It has been shown in mouse models that myDCs are essential for priming antitumor T-cell responses, with type 1 conventional dendritic cells (cDC1), being characterized by the expression of CD103 and dependent on the transcription factor Batf3, mediating CD8+ cytotoxic T lymphocytes (CTL), and type 2 conventional dendritic cells (cDC2) mediating CD4+ T-cell responses against tumor cells [17]. This evidence concerns the gene CD8A and neoplasm.